Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (35)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Suarez, S.
Right arrow Articles by Hickey, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suarez, S.
Right arrow Articles by Hickey, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 48, 431-434
© 2001 The British Society for Antimicrobial Chemotherapy

Brief report

Airways delivery of rifampicin microparticles for the treatment of tuberculosis

Sandra Suareza, Patrick O'Haraa, Masha Kazantsevaa, Christian E. Newcomerb, Roy Hopferc, David N. McMurrayd and Anthony J. Hickeya,*

a School of Pharmacy, and Departments of b Pathology and Laboratory Animal Medicine, and c Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599; d Department of Medical Microbiology and Immunology, College of Medicine, Texas A&M University, System Health Science Center, College Station, TX 77843, USA

A Mycobacterium tuberculosis (H37Rv)-infected guinea pig model was used to screen for targeted delivery to the lungs by insufflation (with lactose excipient) or nebulization, of either rifampicin alone, rifampicin within poly(lactide-co-glycolide) microspheres (R-PLGA) or polymer microparticles alone (PLGA). Animals treated with single and double doses of R-PLGA microspheres exhibited significantly reduced numbers of viable bacteria, inflammation and lung damage compared with lactose-, PLGA- or rifampicin-treated animals 28 days post-infection (P < 0.05). Two doses of R-PLGA resulted in reduced splenic enlargement. These studies support the potential of R-PLGA delivered to the lung to treat pulmonary tuberculosis.

* Corresponding author. Tel: +1-919-962-0223; Fax: +1-919-962-0197; E-mail: ahickey{at}unc.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
R. K. Verma, J. Kaur, K. Kumar, A. B. Yadav, and A. Misra
Intracellular Time Course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary Delivery of Inhalable Microparticles to Mice
Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3195 - 3201.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
M. Yokohira, T. Kuno, K. Yamakawa, K. Hosokawa, Y. Matsuda, N. Hashimoto, S. Suzuki, K. Saoo, and K. Imaida
Lung Toxicity of 16 Fine Particles on Intratracheal Instillation in a Bioassay Model Using F344 Male Rats
Toxicol Pathol, June 1, 2008; 36(4): 620 - 631.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Garcia-Contreras, J. Fiegel, M. J. Telko, K. Elbert, A. Hawi, M. Thomas, J. VerBerkmoes, W. A. Germishuizen, P. B. Fourie, A. J. Hickey, et al.
Inhaled Large Porous Particles of Capreomycin for Treatment of Tuberculosis in a Guinea Pig Model
Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2830 - 2836.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Sharma, P. Muttil, A. B. Yadav, S. K. Rath, V. K. Bajpai, U. Mani, and A. Misra
Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra
J. Antimicrob. Chemother., March 1, 2007; 59(3): 499 - 506.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. Garcia-Contreras, V. Sethuraman, M. Kazantseva, V. Godfrey, and A. J. Hickey
Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig
J. Antimicrob. Chemother., November 1, 2006; 58(5): 980 - 986.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Pandey and G. K. Khuller
Antitubercular inhaled therapy: opportunities, progress and challenges
J. Antimicrob. Chemother., April 1, 2005; 55(4): 430 - 435.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Pandey, A. Sharma, A. Zahoor, S. Sharma, G. K. Khuller, and B. Prasad
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis
J. Antimicrob. Chemother., December 1, 2003; 52(6): 981 - 986.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.